Molecular Testing Labs Earns NGSP (National Glycohemoglobin Standardization Program) Level I Laboratory Certification for Diabetes Blood Test on Dried Blood Spots

VANCOUVER, WA – September 15, 2023 – Molecular Testing Labs, a trailblazer in the field of molecular diagnostics based in Vancouver, Washington, is delighted to announce that they have received the NGSP Level I Laboratory certification for their ground-breaking dried blood spot test for Hemoglobin A1c (HbA1c). 

The NGSP Level I Laboratory certification is an esteemed international recognition that indicates Molecular Testing Labs’ HbA1c test results are precise and standardized and adhere to the advanced requirements for Level I certification. This level ensures that the laboratory can perform high-complexity testing, enabling Molecular Testing Labs to deliver a higher degree of interpretive judgment and advanced analytical techniques in its diabetes monitoring tests. 

“Our mission is to improve access to diagnostics and better decision-based healthcare,” said Eric Strafel, CEO of Molecular Testing Labs. “The NGSP Level I Laboratory certification is a significant milestone that affirms our dried blood spot testing technology meets the same quality, accuracy, and reliability standards that traditional venipuncture whole blood tests have demonstrated. This test has the potential to bridge gaps in testing and accessibility for home care providers, virtual care providers, health plans, and pharmacies managing chronic disease states and struggling to maintain patients’ compliance with annual testing.” 

Molecular Testing Labs’ dried blood spot card test uses capillary blood from a simple finger prick and can be completed without a phlebotomist. The sample is dried on a special card and sent to the lab for analysis. This innovative approach makes diabetes testing more accessible and convenient for patients, eliminating the need for traditional venipuncture. 

The NGSP Level I Laboratory certification, recognizing Molecular Testing Labs’ dedication to quality, standardization, and high-level diagnostic testing capabilities, significantly propels the company’s mission to revolutionize patient care through accessible, high-quality diagnostic testing. 

 About Molecular Testing Labs: 

Headquartered in Vancouver, Washington, Molecular Testing Labs’ leaders are visionary in their approach to precision laboratory diagnostics. They are committed to increasing the accessibility and affordability of diagnostic testing via cutting-edge research and development, advanced logistics, and proprietary technology systems. They provide laboratory solutions through collaborative partnerships with payors, private healthcare institutions, universities, commercial partners, and public health organizations.  

Molecular Testing Labs is a CLIA-certified and CAP-accredited, state-of-the-art reference laboratory that is passionate about bridging the gap and building bonds between the large communities that have access to diagnostics and the smaller, underserved communities that deserve the same access. Molecular Testing Labs is pioneering distribution and specimen collection methods, creating unrestricted access to medical testing where geographic, financial, and stigma barriers create gaps in healthcare delivery.